

CHEMOTHERAPY PERMEATION REPORT



Item Number	PremierPro™ Neoprene Micro 434XX	PremierPro™ Polyisoprene Hybrid 433XX	PremierPro™ Polyisoprene 431XX	PremierPro™ Polyisoprene Underglove 432XX	PremierPro™ Polyisoprene Ortho 436XX	PremierPro™ GAMMEX® Non-Latex PI Micro 435XX	PremierPro™ Latex 441XX	PremierPro™ Latex Underglove 442XX	PremierPro™ Latex Ortho 446XX	PremierPro™ Latex Micro 445XX	GAMMEX® Non-Latex 464XX	GAMMEX® Non-Latex PI Green 461XX	GAMMEX® Non-Latex PI Textured 467XX	ENCORE™ Latex Textured 457XX
Material	Neoprene			Polyisoprene				Latex			Neoprene	Polyisoprene		Latex
CHEMOTHERAPY DRUG														
Bleomycin/Blenoxane (15.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Busulfan (6.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Carboplatin/Paraplatin (10.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Carmustine (3.3 mg/ml)	30.3	23.6	10.2	12.2	6.46	12.2	1.5	31.0	1.0	6.5	30.3	15.5	10.2	1.69
Cisplatin (1.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Cyclophosphamide (20.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	175	>240	>240	>240	>240	>240	>240
Cytarabine (100.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Dacarbazine (10.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Daunorubicin (5.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Docetaxel (10.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Doxorubicin Hydrochloride (2.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Epirubicin/Ellence (2.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Etoposide (20.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Fludarabine (25.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Fluorouracil (50.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Gemcitabine (38.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Idarubicin (1.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Ifosfamide (50.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Irinotecan (20.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Mechlorethamine HCl (1.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Melphalan (5.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Methotrexate (25.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Mitomycin C (0.5 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Mitoxantrone (2.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Oxaliplatin (2.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Paclitaxel (6.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
Rituximab (10.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
ThioTEPA (10.0 mg/ml)	61.0	36.1	11.5	23.8	14.31	23.8	15.26	6.0	3.78	12.5	61.0	15.5	11.5	1.89
Vincristine Sulfate (1.0 mg/ml)	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240	>240
# of drugs listed in US FDA 510K (Indicated in blue)	9/29	29/29	27/29	-	-	-	9/29	-	-	-	9/29	9/29	27/29	-

RATING SYSTEM		
RECOMMENDED The results for this specific chemotherapy drug suggest that the glove would provide an adequate barrier for use in most applications. Breakthrough occurs in >60 minutes.	CAUTION The results require additional consideration to determine suitability for use. Breakthrough occurs in >10 to 60 minutes.	NOT RECOMMENDED Not recommended for use. Breakthrough occurs in ≤10 minutes.

IMPORTANT: Some products have additional chemotherapy drug testing available that are not listed in the FDA 510K. For further information on drugs tested and 510K information, please contact Ansell Customer Service. ASTM D6978 testing performed by a third-party accredited laboratory. Stated breakthrough times were determined under laboratory conditions that may not reflect actual usage. Variation in the environment or a mix of chemotherapy drugs used may impact breakthrough times. Users should test the suitability of this product against their specific chemotherapy drugs and environment. Information accurate as of June 2019. For further updated information, please contact Ansell Customer Service.

Except as noted, Ansell, ® and ™ are trademarks owned by Ansell Limited or one of its affiliates. PremierPro and PremierPro logo are trademarks of Premier Healthcare Alliance, LP. and are used with permission.